The Jackson Laboratory Gene Editing Testing Center (JAX-GETC)
Project Number5U42OD026635-05
Contact PI/Project LeaderMURRAY, STEPHEN A Other PIs
Awardee OrganizationJACKSON LABORATORY
Description
Abstract Text
PROJECT SUMMARY OVERALL SECTION
The JAX Genome Editing Mouse Testing Center (JAX-GEMTC) aims to capitalize on the convergence of rapid
advances in genome editing technology and the maturity of gene therapy platforms to achieve fundamental
breakthroughs in the treatment of genetic disease. To accomplish this mission, the JAX-GEMTC will build novel
reporter mouse line platforms for robust and sensitive detection of editing activity, and use these models to
support the in vivo evaluation of new delivery technologies and editors. This Center draws upon the unique
expertise and unparalleled mouse genetic resources at JAX, fortified by an 80-year history of mouse biology
research. We have assembled a talented, multi-functional team organized into discrete components that
leverage JAX institutional pipelines and resources. The three research components—the Animal Model
Production Unit, the Gene Editing Testing Core, and the Animal Model Resource Core—are tightly coordinated
by the Center leadership, and build primarily upon existing research and management teams. The Center
supplements these pipelines with collaborations that add unique resources and skills to accelerate our
implementation and expand the potential scope of our impact. The overall Aims of the JAX-GEMTC are: 1) To
develop a mouse model resource, including a panel of reporter models, to robustly monitor genome editing
activity and cell-type specificity in vivo. 2) To establish a multi-disciplinary team of experts and to develop a
scalable platform to support the delivery of genome editing components and analysis of editing outcomes. 3) To
engage with and contribute to the Somatic Cell Genome Editing (SCGE) consortium by deploying systems to
share both data and animal resources. 4) To develop a framework for future collaborative expansion of our
program, taking advantage of our expertise and the scalability of our mouse model generation and in vivo
manipulation platforms. The successful completion of these aims will fuel the goals of the SCGE program, which
aims to improve genome editing technologies to accelerate the translation of this technology into clinical
applications and maximize the potential to treat as many diseases as possible.
Public Health Relevance Statement
PROJECT NARRATIVE OVERALL SECTION
The revolution in gene editing technology promises to transform the development of therapeutics to treat
human disease. As part of the Somatic Cell Genome Editing consortium, the goal of this project is to build
mouse resources and provide an animal model testing platform to support the optimization of novel genome
editing technologies for future translational applications.
NIH Spending Category
No NIH Spending Category available.
Project Terms
Animal ModelBiologyCRISPR/Cas technologyCollaborationsDetectionDevelopmentDiseaseFacultyFormulationFutureGene TransferGenerationsGenesGenetic DiseasesGenomeGoalsKnockout MiceLeadershipMissionModelingModificationMonitorMusOutcomePharmaceutical PreparationsPharmacologyPhenotypePreclinical TestingProductionReagentRecording of previous eventsReporterResearchResourcesServicesSpecificitySystemTalentsTechnologyTestingThe Jackson LaboratoryTranslationsanimal resourcebasecell typeclinical applicationdata resourceexperiencegene therapygenetic resourcegenome editinghuman diseaseimprovedin vivoin vivo evaluationloss of functionmouse geneticsmouse modelmultidisciplinarynovelprecision geneticsprogramsskillssomatic cell gene editingtherapeutic developmenttherapy outcometranslational applicationstranslational impact
No Sub Projects information available for 5U42OD026635-05
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5U42OD026635-05
Patents
No Patents information available for 5U42OD026635-05
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5U42OD026635-05
Clinical Studies
No Clinical Studies information available for 5U42OD026635-05
News and More
Related News Releases
No news release information available for 5U42OD026635-05
History
No Historical information available for 5U42OD026635-05
Similar Projects
No Similar Projects information available for 5U42OD026635-05